Literature DB >> 10455065

Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function.

F G Spinale1, M L Coker, S R Krombach, R Mukherjee, H Hallak, W V Houck, M J Clair, S B Kribbs, L L Johnson, J T Peterson, M R Zile.   

Abstract

The development of congestive heart failure (CHF) is associated with left ventricle (LV) dilation and myocardial remodeling. The matrix metalloproteinases (MMPs) play a significant role in extracellular remodeling, and recent studies have demonstrated increased MMP expression and activity with CHF. Whether increased MMP activity directly contributes to the LV remodeling with CHF remains unknown. Accordingly, this study examined the effects of chronic MMP inhibition (MMPi) on LV size and function during the progression of CHF. Pigs were assigned to the following groups: (1) CHF, rapid pacing for 3 weeks at 240 bpm (n=12); (2) CHF/MMPi, rapid pacing and concomitant MMPi (PD166793, 20 mg/kg per day [n=10]), and (3) control (n=11). With pacing CHF, LV fractional shortening was reduced (19+/-1 versus 45+/-1%), and end-diastolic dimension increased (5.67+/-0.11 versus 3.55+/-0.05 cm), compared with baseline values (P<0.05). In the CHF/MMPi group, LV endocardial shortening increased (25+/-2%) and the end-diastolic dimension was reduced (4.92+/-0.17 cm) compared with CHF-only values (P<0.05). LV midwall shortening was reduced to a comparable degree in the CHF-only and CHF/MMPi groups. LV peak wall stress increased 3-fold with pacing CHF compared with controls and was significantly reduced in the CHF/MMPi group. LV myocardial stiffness was unchanged with CHF but was increased in the CHF/MMPi group. LV myocyte length was increased with pacing CHF compared with controls (180+/-3 versus 125+/-4 microm, P<0.05) and was reduced in the CHF/MMPi group (169+/-4 microm, P<0.05). Basal-state myocyte shortening velocity was reduced with pacing CHF compared with controls (33+/-2 versus 66+/-1 microm/s, P<0.05) and was unchanged in the CHF/MMPi group (31+/-2 microm/s). Using an ex vivo assay system, myocardial MMP activity was increased with pacing CHF and was reduced with chronic MMPi. In summary, concomitant MMPi with developing CHF limited LV dilation and reduced wall stress. These results suggest that increased myocardial MMP activity contributes to LV myocardial remodeling in developing CHF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455065     DOI: 10.1161/01.res.85.4.364

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  57 in total

Review 1.  Molecular and cellular mechanisms of myocardial remodeling.

Authors:  Melanie Maytin; Wilson S Colucci
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

2.  Matrix metalloproteinases: not-so-innocent bystanders in heart failure.

Authors:  R T Lee; P Libby
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

3.  Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.

Authors:  Takashi Yokota; Tomohiro Osanai; Kenji Hanada; Motoi Kushibiki; Naoki Abe; Koichi Oikawa; Hirofumi Tomita; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Ken Okumura
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

Review 4.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

5.  Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.

Authors:  M Fassbach; B Schwartzkopff
Journal:  Z Kardiol       Date:  2005-05

6.  Matrix metalloproteinase therapy in heart failure.

Authors:  Francis G Spinale; Nikole M Wilbur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

7.  Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure.

Authors:  Tobias Täger; Clara Wiebalck; Hanna Fröhlich; Anna Corletto; Hugo A Katus; Lutz Frankenstein
Journal:  Clin Res Cardiol       Date:  2017-08-04       Impact factor: 5.460

Review 8.  The role of nitric oxide in the failing heart.

Authors:  W J Paulus
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 9.  Intramyocardial fibroblast myocyte communication.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

10.  Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study.

Authors:  Valentina O Puntmann; Peter C Taylor; Andrew Barr; Bernhard Schnackenburg; Cosima Jahnke; Ingo Paetsch
Journal:  Rheumatology (Oxford)       Date:  2009-12-21       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.